May 15th 2017EP. 1: Impact of the EMPA-REG Study in Type 2 Diabetes
May 15th 2017EP. 2: Cardiovascular Outcomes With GLP-1 Receptor Agonists in Type 2 Diabetes
May 15th 2017EP. 3: SGLT2 Inhibition and CVD Outcomes in Type 2 Diabetes
May 15th 2017EP. 4: Cardiovascular Outcomes Trials With Anti-Diabetes Medications
May 15th 2017EP. 5: Understanding Heart Failure in Diabetes
May 15th 2017EP. 6: Big Data and CVD Benefits of Anti-Diabetes Medications
May 15th 2017EP. 7: Designing Better Cardiovascular Outcomes Trials in Diabetes
May 15th 2017EP. 8: Big Data Analysis and Clinical Decision Making in Diabetes
May 15th 2017EP. 9: Cost-Effectiveness and Coverage Decisions in Diabetes
May 15th 2017EP. 10: Shared Decision-Making in Diabetes
May 15th 2017EP. 11: A Historic View on CV Outcomes in Diabetes
May 15th 2017EP. 12: Impact of EMPA-REG OUTCOME
May 15th 2017EP. 13: Results From the CANVAS Trial
May 15th 2017EP. 14: Complexities in Diabetes Care in 2017
May 15th 2017EP. 15: Diabetes: Shifting the Mindset for Cardiovascular Benefits
May 15th 2017EP. 16: Cardiovascular Benefit With SGLT2 Inhibition
May 15th 2017EP. 17: GLP-1 Receptor Agonists: Initial Cardiovascular Evidence
May 15th 2017EP. 18: Understanding Cardiovascular Benefit With the LEADER Trial
May 15th 2017EP. 19: Impact of Cardiovascular Evidence on Diabetes
